Skip to main content
Erschienen in:

13.10.2022 | Brief Research Article

Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis

verfasst von: Consuelo Jordán de Luna, Esteve Fernández, Ricard Mesía, Ana Clopés

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The Catalan Institute of Oncology (ICO) is a Comprehensive Cancer Center (CCC) responsible for the oncological care of 46% of the Catalan population.

Objective

Given the increasing and ongoing approval of onco-hematological treatments, the professionals at the ICO decided to have clinical practice guidelines (called ICOPraxis) based on available evidence. In this report, we intend to share how the ICOPraxis has developed and what its impact has been in the 14 years it has been running.

Results

In the 14 years, since the project has been running, 17 clinical practice guidelines (some of them with several editions) have been prepared for major onco-hematology clinical conditions. These guidelines will be utilized in the four ICO centers (Girona, Badalona, Tarragona, and Hospitalet) and ICO works in a network with 18 regional hospitals. Between 2018 and 2022, the guidelines have been viewed 38.645 times and downloaded 24.614 times, with an average time spent on each page of 3 min. The ICOPraxis have been consulted in 25 countries in America (3.163 views), 20 countries in Europe (35.365 views), 10 countries in Asia (36 views), and 3 countries in Africa (12 views). The country with the highest number of downloads is Spain with a total of 34.742 downloads (Analytics [Internet]).

Conclusion

The ICOPraxis have succeeded in establishing an evidence-based system that facilitates prescription decision-making according to the established harmonization process and reduction in variability in treatments, increasing equity in our population.
Literatur
1.
Zurück zum Zitat Simone JV. Understanding cancer centers. J Clin Oncol. 2002;20(23):4503–7.CrossRef Simone JV. Understanding cancer centers. J Clin Oncol. 2002;20(23):4503–7.CrossRef
4.
Zurück zum Zitat Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–66.CrossRef Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–66.CrossRef
5.
Zurück zum Zitat Rajkumar SV. The High Cost of Cancer Drugs: What Can We Do? Hematological Oncol. 2019;37(S2):172–172.CrossRef Rajkumar SV. The High Cost of Cancer Drugs: What Can We Do? Hematological Oncol. 2019;37(S2):172–172.CrossRef
6.
Zurück zum Zitat Song P, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong J, et al. The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends. 2010;4(6):283–7. Song P, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong J, et al. The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends. 2010;4(6):283–7.
7.
Zurück zum Zitat Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical Practice Guidelines: Directions for a New Program [Internet]. Field MJ, Lohr KN, editors. Washington (DC): National Academies Press (US); 1990 [cited 2021 Feb 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK235751/ Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical Practice Guidelines: Directions for a New Program [Internet]. Field MJ, Lohr KN, editors. Washington (DC): National Academies Press (US); 1990 [cited 2021 Feb 5]. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK235751/​
8.
Zurück zum Zitat Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.CrossRef Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.CrossRef
10.
Zurück zum Zitat Grupo de trabajo GENESIS (Grupo de Evaluación de Novedades. Estandarización e Investigación en Selección de medicamentos) de la SEFH (Sociedad española de Farmacia Hospitalaria) [Internet]. [cited 2020 May 3]. Available from: https://gruposdetrabajo.sefh.es/genesis/ Grupo de trabajo GENESIS (Grupo de Evaluación de Novedades. Estandarización e Investigación en Selección de medicamentos) de la SEFH (Sociedad española de Farmacia Hospitalaria) [Internet]. [cited 2020 May 3]. Available from: https://​gruposdetrabajo.​sefh.​es/​genesis/​
11.
Zurück zum Zitat Frutos Pérez-Surio A, Jordán de Luna C. Guidelines for evidence synthesis reporting: medications. Eur J Hosp Pharm. 2020;27(5):306–9.CrossRef Frutos Pérez-Surio A, Jordán de Luna C. Guidelines for evidence synthesis reporting: medications. Eur J Hosp Pharm. 2020;27(5):306–9.CrossRef
12.
Zurück zum Zitat Dreier G, Löhler J. Evidence and evidence gaps – an introduction. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016;15:Doc11. Dreier G, Löhler J. Evidence and evidence gaps – an introduction. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016;15:Doc11.
13.
Zurück zum Zitat Müller T. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy. Eur J Health Econ. 2008;9(Suppl 1):1–3.CrossRef Müller T. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy. Eur J Health Econ. 2008;9(Suppl 1):1–3.CrossRef
14.
Zurück zum Zitat Shekelle P, Woolf S, Grimshaw JM, Schünemann HJ, Eccles MP. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. Implement Sci. 2012;7(1):62.CrossRef Shekelle P, Woolf S, Grimshaw JM, Schünemann HJ, Eccles MP. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. Implement Sci. 2012;7(1):62.CrossRef
15.
Zurück zum Zitat Barasa EW, Molyneux S, English M, Cleary S. Setting Healthcare priorities at the macro and meso levels: a framework for evaluation. Int J Health Policy Manag. 2015;4(11):719–32.CrossRef Barasa EW, Molyneux S, English M, Cleary S. Setting Healthcare priorities at the macro and meso levels: a framework for evaluation. Int J Health Policy Manag. 2015;4(11):719–32.CrossRef
16.
Zurück zum Zitat Sharp CA, Swaithes L, Ellis B, Dziedzic K, Walsh N. Implementation research: making better use of evidence to improve healthcare. Rheumatology (Oxford). 2020;59(8):1799–801.CrossRef Sharp CA, Swaithes L, Ellis B, Dziedzic K, Walsh N. Implementation research: making better use of evidence to improve healthcare. Rheumatology (Oxford). 2020;59(8):1799–801.CrossRef
17.
Zurück zum Zitat Tomasone JR, Kauffeldt KD, Chaudhary R, Brouwers MC. Effectiveness of guideline dissemination and implementation strategies on health care professionals’ behaviour and patient outcomes in the cancer care context: a systematic review. Implementation Sci. 2020;15(1):41.CrossRef Tomasone JR, Kauffeldt KD, Chaudhary R, Brouwers MC. Effectiveness of guideline dissemination and implementation strategies on health care professionals’ behaviour and patient outcomes in the cancer care context: a systematic review. Implementation Sci. 2020;15(1):41.CrossRef
18.
Zurück zum Zitat Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and strategies in guideline implementation—a scoping review. Healthcare (Basel). 2016;4(3):36.CrossRef Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and strategies in guideline implementation—a scoping review. Healthcare (Basel). 2016;4(3):36.CrossRef
21.
Zurück zum Zitat Guidelines I of M (US) C on S for DTCP, Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Current Best Practices and Proposed Standards for Development of Trustworthy CPGs: Part 1, Getting Started [Internet]. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011 [cited 2022 Aug 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209537/ Guidelines I of M (US) C on S for DTCP, Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Current Best Practices and Proposed Standards for Development of Trustworthy CPGs: Part 1, Getting Started [Internet]. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011 [cited 2022 Aug 17]. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK209537/​
22.
Zurück zum Zitat Wailoo A, Roberts J, Brazier J, McCabe C. Efficiency, equity, and NICE clinical guidelines. BMJ. 2004;328(7439):536–7.CrossRef Wailoo A, Roberts J, Brazier J, McCabe C. Efficiency, equity, and NICE clinical guidelines. BMJ. 2004;328(7439):536–7.CrossRef
23.
Zurück zum Zitat Gabbay J, le May A. Evidence based guidelines or collectively constructed “mindlines?” Ethnographic study of knowledge management in primary care. BMJ. 2004;329(7473):1013.CrossRef Gabbay J, le May A. Evidence based guidelines or collectively constructed “mindlines?” Ethnographic study of knowledge management in primary care. BMJ. 2004;329(7473):1013.CrossRef
24.
Zurück zum Zitat Nicol E. Sustainability in healthcare: efficiency, effectiveness, economics and the environment. Future Healthc J. 2018;5(2):81.CrossRef Nicol E. Sustainability in healthcare: efficiency, effectiveness, ­economics and the environment. Future Healthc J. 2018;5(2):81.CrossRef
26.
28.
Zurück zum Zitat Lyratzopoulos G, Barnes S, Stegenga H, Peden S, Campbell B. Updating clinical practice recommendations: is it worthwhile and when? Int J Technol Assess Health Care. 2012;28(1):29–35.CrossRef Lyratzopoulos G, Barnes S, Stegenga H, Peden S, Campbell B. Updating clinical practice recommendations: is it worthwhile and when? Int J Technol Assess Health Care. 2012;28(1):29–35.CrossRef
29.
Zurück zum Zitat Martínez García L, Sanabria AJ, García Alvarez E, Trujillo-Martín MM, Etxeandia-Ikobaltzeta I, Kotzeva A, et al. The validity of recommendations from clinical guidelines: a survival analysis. CMAJ. 2014;186(16):1211–9.CrossRef Martínez García L, Sanabria AJ, García Alvarez E, Trujillo-Martín MM, Etxeandia-Ikobaltzeta I, Kotzeva A, et al. The validity of recommendations from clinical guidelines: a survival analysis. CMAJ. 2014;186(16):1211–9.CrossRef
Metadaten
Titel
Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis
verfasst von
Consuelo Jordán de Luna
Esteve Fernández
Ricard Mesía
Ana Clopés
Publikationsdatum
13.10.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-022-02962-0

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.